Project Grant HT94252410258
Award Date
4/15/24
Completion Date
4/14/26
Dollars Obligated
$587K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
East Watertown, MA 02472, USA
Similar Awards
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This federal Project Grant award of $1,078,882.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research focused on developing innovative therapeutic approaches for amyotrophic lateral sclerosis (ALS) by investigating the multimodal therapeutic actions of donor and host neural stem cells. Key research services include consultation on surgical intervention methods for delivering compounds...
This Project Grant award of $798,272.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research at The Johns Hopkins University to test the use of Wnt inhibitors as a potential therapeutic approach to reverse TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The research project will be conducted over a 2-year period from March 2025 to March 2027, with the goal of advancing...
This $680,591 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund a research project at Wayfinder Biosciences Inc. in Seattle, WA. The project aims to develop a novel small molecule screening approach for directly and selectively targeting repeat expansion RNA in C9ORF72 amyotrophic lateral sclerosis (ALS). The award period runs from June 15, 2025 to June 14, 2026 and seeks to advance disease prevention,...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,875 project grant to the University of Florida (UF) Division of Sponsored Research. The grant, awarded on April 1, 2024, supports the development of heterobifunctional degraders of TDP-43 as a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS). Under this grant, the University of North Carolina at Chapel Hill (UNC-CH) Office of Sponsored Research is serving as a sub-awardee....
This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....
The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...